How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
Source ↗
👁 0
💬 0
Pfizer's oncology unit displays mixed Q1 trends as key drugs and biosimilars offset Ibrance declines ahead of earnings on May 5
Comments (0)